Biotech Values

[DewDiligence]

The existence of a proprietary patented process speaks to the “willfulness” (i.e. the lack thereof) of NVS/MNTA’s infringement in the event the Judge finds that NVS/MNTA’s generic Copaxone does infringe.

When was the last time treble damages were assessed in a generic-drug case? I’m not sure if it’s ever happened.